<DOC>
	<DOCNO>NCT00004115</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know whether monoclonal antibody therapy effective observation ovarian cancer primary peritoneal cancer remission . PURPOSE : Randomized phase III trial compare effectiveness monoclonal antibody therapy observation treat patient ovarian cancer primary peritoneal cancer remission follow surgery chemotherapy .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Ovarian Cancer Primary Peritoneal Cancer Remission Following Surgery Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy yttrium Y 90 monoclonal antibody HMFG1 , term survival , patient ovarian epithelial carcinoma remission debulking surgery platinum-based chemotherapy . - Determine toxicity tolerability treatment regimen patient . - Determine quality life patient treat regimen . - Evaluate treatment regimen , term time relapse , ECOG performance status , frequency hospitalization , change concurrent medication , incidence severity adverse event , patient population . OUTLINE : This randomize , parallel , multicenter study . Patients randomize one two treatment arm . - Arm I : Patients receive standard therapy ( observation ) . - Arm II : After image study peritoneal cavity verify adequate fluid distribution , patient receive yttrium Y 90 monoclonal antibody HMFG1 intraperitoneally 1 minute . Quality life assess patient prior randomization , week 4 8 , 3 month , every 3 month thereafter . Patients arm I follow week 1 , 4 , 8 . Patients arm II follow weekly 6 week week 8 12 . All patient follow every 3 month 3 year . PROJECTED ACCRUAL : A total 420 patient ( 210 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IC , II , III , IV ovarian epithelial carcinoma primary peritoneal serous carcinoma Prior complete response 1 platinumbased chemotherapy regimen consist least 5 course Absence disease physical radiological exam ( CT scan/MRI ) CA 125 normal No visible evidence malignant disease secondlook laparoscopy No disease relapse even complete response second course chemotherapy Prior bilateral oophorectomy without salpingectomy , omentectomy , total partial abdominal hysterectomy require No known metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10.0 g/dL Hepatic : SGOT/SGPT great 2 time upper limit normal Renal : Creatinine great 2.0 mg/dL Other : No malignancy except basal cell skin cancer No serious physical psychiatric disease would preclude study entry No significant loculation would preclude good distribution study medication Human antimouse antibody negative PRIOR CONCURRENT THERAPY : Biologic therapy : No prior murine antibody Chemotherapy : See Disease Characteristics No 48 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No concurrent participation trial involve adjuvant cancer treatment No concurrent experimental therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>